"It was 2022, and he was one of 11 volunteers in the world's first clinical study with "extended DMT," nicknamed DMTx, at Imperial College London. The idea had been suggested six years earlier in a paper by neurobiologist Andrew Gallimore and psychiatrist Rick Strassman, which argued that a technology called target-controlled intravenous infusion, originally developed to maintain steady levels of anesthesia during surgery, could be repurposed to prolong the DMT state."
"For Gallimore, one of the goals behind DMTx is to study an especially strange aspect of the DMT experience: perceived encounters with nonhuman, seemingly superintelligent entities. On March 18, he and a team of experts will launch a new psychedelic retreat center-slash-research facility on the tiny Caribbean island of Bequia aimed in part at establishing sustained, two-way communication with these beings."
Anton Bilton participated in the world's first clinical study of extended DMT (DMTx) at Imperial College London, where EEG electrodes monitored his brain activity while DMT was administered intravenously. Unlike typical DMT experiences lasting 10-15 minutes, the extended infusion produced a 30-minute peak effect. The study, based on a proposal by neurobiologist Andrew Gallimore and psychiatrist Rick Strassman, uses target-controlled intravenous infusion technology to maintain steady DMT levels. Gallimore's research focuses on a distinctive aspect of DMT experiences: perceived encounters with seemingly superintelligent nonhuman entities. He is establishing a research facility in the Caribbean to investigate sustained communication with these beings.
#dmt-research #psychedelic-neuroscience #extended-dmt-infusion #nonhuman-entities #clinical-psychedelic-studies
Read at WIRED
Unable to calculate read time
Collection
[
|
...
]